Recognize
An engineered antibody fragment is selected to bind a specific bacterium, virus, or protein analyte.
A programmable biosensor platform
Leucine Lock DX is developing biosensors that combine target-specific recognition with enzyme-powered signal amplification—designed to preserve sensitivity while delivering practical results in minutes.
*Platform targets and company-reported development goals; performance varies by assay and requires validation.
The core idea
Traditional rapid tests often force a tradeoff between speed and sensitivity. The Leucine Lock platform is being engineered to address both through a molecular switch coupled to an amplifying enzyme response.
An engineered antibody fragment is selected to bind a specific bacterium, virus, or protein analyte.
Target binding changes the sensor configuration, releasing the Leucine Lock-controlled activity.
The activated enzyme generates many signal molecules from one recognition event, strengthening the readout.
The output can be designed as color, light, or an electrical signal—qualitative or quantitative.
One architecture, many possibilities
Simple tube-based tests designed around a clear positive or negative result.
Instrument-based formats for measuring protein analytes such as insulin.
Multiplex concepts that could distinguish several respiratory targets in a single workflow.
Kinetics, recognition chemistry, amplification, and readout can be tailored to the application.
Partners & investors